GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Betta Pharmaceuticals Co Ltd (SZSE:300558) » Definitions » Return-on-Tangible-Asset

Betta Pharmaceuticals Co (SZSE:300558) Return-on-Tangible-Asset : 7.02% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Betta Pharmaceuticals Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Betta Pharmaceuticals Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥400 Mil. Betta Pharmaceuticals Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥5,699 Mil. Therefore, Betta Pharmaceuticals Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 7.02%.

The historical rank and industry rank for Betta Pharmaceuticals Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300558' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.52   Med: 11.23   Max: 47.38
Current: 7.11

During the past 13 years, Betta Pharmaceuticals Co's highest Return-on-Tangible-Asset was 47.38%. The lowest was 3.52%. And the median was 11.23%.

SZSE:300558's Return-on-Tangible-Asset is ranked better than
72.09% of 1021 companies
in the Drug Manufacturers industry
Industry Median: 2.68 vs SZSE:300558: 7.11

Betta Pharmaceuticals Co Return-on-Tangible-Asset Historical Data

The historical data trend for Betta Pharmaceuticals Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Betta Pharmaceuticals Co Return-on-Tangible-Asset Chart

Betta Pharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.63 11.83 3.52 6.69 7.10

Betta Pharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.95 8.94 13.59 -0.95 7.02

Competitive Comparison of Betta Pharmaceuticals Co's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Betta Pharmaceuticals Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Betta Pharmaceuticals Co's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Betta Pharmaceuticals Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Betta Pharmaceuticals Co's Return-on-Tangible-Asset falls into.


;
;

Betta Pharmaceuticals Co Return-on-Tangible-Asset Calculation

Betta Pharmaceuticals Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=402.569/( (5571.195+5768.504)/ 2 )
=402.569/5669.8495
=7.10 %

Betta Pharmaceuticals Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=400.356/( (5768.504+5630.355)/ 2 )
=400.356/5699.4295
=7.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


Betta Pharmaceuticals Co  (SZSE:300558) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Betta Pharmaceuticals Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Betta Pharmaceuticals Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Betta Pharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
No. 355, Xingzhong Road, Economic and Technological Development Zone, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311100
Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.
Executives
Wang Jia Bing Directors, executives
Ding Lie Ming Directors, executives
Cai Wan Yu Executives

Betta Pharmaceuticals Co Headlines

No Headlines